Medical and Chemical TOC Members

I, Emmanuel Addo-Yobo nominated by UNEP Ozone Secretariat, residing in Ghana, and a member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Associate Professor in the Department of Child Health, Kwame Nkrumah University of Science and Technology, and Honorary Consultant Paediatrician in the Directorate of Child Health of Komfo Anokye Teaching Hospital, Kumasi, Ghana. My responsibilities include general paediatric clinical care and clinical teaching of undergraduate and postgraduate medical students with special interest in paediatric respiratory disorders. I am is the physician-in-charge of Paediatric Asthma Clinic in the hospital. I have been involved in several research activities on childhood asthma epidemiology in Ghana as Principal or Co-Investigator, some of which have been sponsored partly or fully by pharmaceutical companies. I attended an American Academy of Allergy Asthma and Immunology (AAAAI) meeting sponsored by a pharmaceutical company in 1999. I do not receive any form of remuneration from any drug companies. I have, however, given educational lectures to medical personnel on childhood asthma in Ghana which were sponsored by drug companies in a purely academic capacity. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following:
   • Proprietary interests: I do not have any proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions:
   • My business has an interest in the topics of the Montreal Protocol with regard to my patients with asthma and COPD who may be using MDIs containing ODS where there are no other affordable and effective alternatives. My spouse is a business secretary working with a local financial institution in Ghana and has no interests in matters before the Protocol.
   • Government advice and other policy development: I served as a member of the National Expert Committee for the review of Standard Treatment Guidelines for Ghana (2016-2017). My role in this Committee included advising prescribers on safe and cost-effective treatments for asthma and COPD, and other disorders in my capacity as a clinician.
   • Paid research activities, fellowships or grants: I am not involved in any paid research activities, fellowships or grants relevant to the MCTOC activity. 
   • Other interests: None
5. The source of funding for my participation in the work of the Medical Technical Options Committee has been the Ozone Secretariat of the United Nations Environmental Programme (UNEP).
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Professor Emmanuel Addo-Yobo 
Date: 18th March 2019

I, Fatima Al-Shatti, nominated by Kuwait, residing in Kuwait, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1) I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.

2) I am Environment Advisor with Kuwait Environment Public Authority. I am responsible for environment.

3) This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.

4) My interests , and those of my personal partner and dependents, include the following

a. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).

b. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.

c. Employment, consultancy, directorship or other positions: Except for my work for Kuwait Petroleum Corporation, neither I nor my family are employed by, do not consult for, and do not serve as a director of or hold any other position for any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel.

d. Government advice and other policy development: None

e. Paid research activities, fellowships or grants: No conflict

f. Other interests: No conflict

5) The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is UNEP’s Ozone Secretariat.

6) Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.

7) I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.

8) I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.

9) I understand that this DOI will expire no later than one year after I have signed it.

Name: Fatima Al-Shatti

Date: 8th April 2019

I, Paul J. Atkins, nominated by USA and residing in the United States, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Vice President at Oriel Therapeutics Inc (a Novartis company). My responsibilities include general management and input in to programs focused on the technical development and manufacture of inhaled medicines.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner, include the following -
   1. Proprietary interests: None
   2. Financial interests: Shares in Novartis and my spouse owns shares in her employer (GSK a manufacturer of inhaled medicines)
   3. Employment, consultancy, directorship or other positions: Currently employed by Novartis, no consulting interests
   4. Government advice and other policy development: None
   5. Paid research activities, fellowships or grants: None
   6. Other interests: N/A
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is either my employer or personal funds
6. Pursuant to paragraph 11 of the COI Guidelines I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussions and decisions on topics related to the information that I have declined to disclose.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Paul J. Atkins PhD.

18^th March 2019

I, William Auriemma, nominated by and residing in the United States of America, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
2. I serve as Chief Executive Officer of Diversified CPC International, Inc. engaged in the supply of aerosol propellants to the consumer products industry. We do extensive work in determining commercial viability of “next generation” propellant systems. My role as Past Chairman of the Household & Commercial Products Association allows for direct interaction with U.S. regulatory agencies.
3. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
4. My interests, and those of my personal partner and dependents, include the following:
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: My company works closely with major U.S. based manufacturers of low GWP substances and is the marketing and distribution arm of these products to the aerosol and medical device industries.
   • Government advice and other policy development: See above under item c.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is our company, Diversified CPC International, Inc. and they will bear all related costs. There are no consulting fees involved.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:  William Auriemma

Date:    March 13, 2019

I, Olga Blinova, nominated by the Russian Federation, residing in the Russian Federation, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
2. I am a full-time, salaried employee at Russian Scientific Center “Applied Chemistry”, based in the Russian Federation, which develop manufacture processes for fluorinated substances. I work for the company as Leading Researcher of Fluorine Chemistry Department. My responsibilities include research in the area of fluorine chemistry.
3. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Except for my work for Russian Scientific Center “Applied Chemistry”, neither I nor my family are employed by, do not consult for, do not serve as a director of or hold any other position for any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel.
   • Government advice and other policy development: none
   • Paid research activities, fellowships or grants: no conflict
   • Other interests: no conflict
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is UNEP
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Olga Blinova

Date: March 13 2019

I, Steve Burns, nominated by and residing in UK, a member of the Medical and Chemicals Technical Options Committee, declare as follows.

1. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
2. I am VP Project Leadership at AstraZeneca Plc. My responsibilities include strategy, planning and execution of AstraZeneca’s pharmaceutical development projects (including provision of technical support to on market brands)
3. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have any proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces) except via the share awards issued to me under the AstraZeneca Long Term Incentive plan (see financial interests below)
   • Financial interests: I have been awarded shares as part of the AstraZeneca Plc Long Term Incentive scheme. These shares vest and become available to me following a vesting period of three years subject to performance criteria being met. The performance criteria include financial performance which is in part linked to the sale of products containing HFA propellants.
   • I am employed by AstraZeneca which offers for sale pressurised metered dose inhalers containing HFA propellants
   • The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is AstraZeneca
5. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
6. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
7. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
8. I understand that this DOI will expire no later than one year after I have signed it.

Name: Steve Burns

Date: 16^th April 2018

I, Jorge Osvaldo Cáneva, nominated by Argentina and residing in Argentina, Member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Chief of the Pulmonary Section at the University Hospital of the Favaloro Foundation, Buenos Aires, Argentina. Besides, I belong as Member of the Pulmonary Hypertension Group and the Intrathoracic Transplantation Group of the same institution. My responsibilities include medical assistance of patients with moderate and severe respiratory and cardiopulmonary diseases referred to this institution, teaching at the University Medical School of the Favaloro Foundation and research in pulmonary vascular diseases, chronic airway diseases and lung transplantation.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following

1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
2. Financial interests: I do not own stock in companies producing ODS or alternatives or substitutes to ODS, and do not have an interest in the outcome of essential use nominations.
3. Employment, consultancy, directorship or other positions:  I have interest in the topics of the Montreal Protocol based on the fact that I take care of patients with severe respiratory and cardiorespiratory diseases in the main institution dedicated to intrathoracic transplantation in Argentina, patients that usually are treated with all inhaled therapies commercially available. I am the Chief of the Pulmonary Section at the University Hospital of the Favaloro Foundation (www.fundacionfavaloro.org; BuenosAires, Argentina) since 2000, and Professor of Internal Medicine of the University Medical School at the same institution. I have been nominated as Professor of the International Master in Pulmonary Hypertension sponsored by the Spanish Society of Cardiology for the period 2014-2016 and 2016-2018. Furthermore, he has been Chairman of the VIII Latin American Symposium in Pulmonary Hypertension that took place in Sao Paulo, Brazil, July 2016, sponsored  by Bayer. Currently I state as Ex-President of the Argentine Association of  Respiratory Medicine (Asociación Argentina de Medicina Respiratoria; AAMR; www.aamr.org.ar), main association in Pulmonary Medicine in Argentina, and was Member of the Scientific Committee of the 2015 Annual Meeting of this society.  I serve as member of the Editorial Board of the European Respiratory Society (ERS) since 2013. I was Governor of the American College of Chest Physician (ACCP; www.chestnet.org) in Argentina between the period 2006-2009. I am the Coordinator of the Bi-National Programme for Pulmonary and Cardiopulmonary Transplantation between Argentina and Uruguay, since 2003. I have been involved in severe respiratory diseases, pulmonary vascular diseases and lung transplantation programmes. I do not own stock in companies producing ODS or alternatives or substitutes to ODS; I do not consult for organizations seeking to phase out ODS. My spouse, has no relationship with any pharmaceutical company. Neither my spouse nor I, do not receive any honorarium or grant from the government, national or international non-for-profit organization.
4. Government advice and other policy development: I do not provide any government advice.
5. Paid research activities, fellowships or grants: During 2003 and 2004, I was involved in consultation for AstraZeneca Argentina about dry powder inhalers (DPI). Between 1993 and 2008, I have served as independent consultant on long-term oxygen therapy for Air Liquide Argentina. I am Principal Investigator (PI) of the following randomized clinical trials (RCTs) in patients suffering from pulmonary hypertension: SERAPHIN 303-OL and GRIPHON 303-OL (sponsored by Actelion Pharmaceuticals, Switzerland), CATALYST (sponsored by Reata Pharmaceuticals, USA), EXPERT (sponsored by Bayer, Germany) and PERFORMA (sponsored by Bagó, Argentina).
6. Other interests: None.

5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committeeis: UNEP’s Ozone Secretariat has paid travel to MCTOC meetings.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jorge Osvaldo Cáneva

Date: 5th February 2018

I, Richard J, Cooke, nominated by Canada, residing in Canada, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
2. I am President and Principle Consultant at Man-West Environmental Group Ltd., a company engaged in environmental consulting. My responsibilities include acting as an independent consultant directing and supporting work in the areas of related to waste management, contaminated sites management, and the demonstration of technologies for chemicals destruction under requirements applied by the Stockholm Convention on Persistent Organic Pollutants, and the Montreal Protocol. Principle clients include Implementing Agencies for the GEF and MLF.
3. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
4. My interests, and those of my personal partner and dependents, include the following: 
   • Proprietary interests: I do not have any proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). projecs
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Current or potentially active assignments in 2019 possibly relevant to the MCTOC are: MLF/GEF End of Life ODS/HFC Destruction Demonstration in projects, GEF POPs Elimination Projects in Turkey, Moldova, Belarus, and Arctic Council POPs Destruction Demonstrations in Russia.
   • Government advice and other policy development: The above projects involve provision of advice on policy issues and program implementation to the respective governments that may be relevant to the MCTOC activity.
   • Paid research activities, fellowships or grants: None
   • Other interests: Protection of Rocky Mountain wildlife habitat connectivity, particularly large carnivores.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Man-West Environmental Ltd. in which I am the principle shareholder, making my participation effectively self-funded.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Richard J. Cooke

Date: March 18, 2019

I,Davide Dalle Fusine, nominated byItaly, residing inShanghai,China, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I amGeneral Manager and Legal Representative at Chiesi Pharmaceutical Shanghai Co. Ltd.and my responsibilities include the management of all the activities of Chiesi Farmaceutici S.p.A. in People Republic of China.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following:

1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
3. Employment, consultancy, directorship or other positions: I have an interest in the topics of Montreal Protocol based on the fact that, as employee of Chiesi Group, I am engaged in the development and commercialization of pMDI and DPI products.
4. Government advice and other policy development: I do not provide any advice to any governmental authority.
5. Paid research activities, fellowships or grants: I have not any other relationship than the labor relationship with Chiesi Farmaceutici SpA.
6. Other interests: None.

5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee isChiesi Pharmaceutical Shanghai Co. Ltd.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Davide Dalle Fusine

Date: February 1st 2018

I, Maureen George, nominated nominated by the United States, residing in the United States, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am an Associate Professor at Columbia University School of Nursing. My responsibilities include conducting an independent program of research in asthma and respiratory health in vulnerable populations, teaching in the PhD and master’s nursing programs, and meeting other service requirements.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests[i], and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (add description of interest; relevant financial relationships between members should be disclosed)
   • Employment, consultancy, directorship or other positions: Honoraria received for advisory/consultant roles with Astra-Zeneca and Teva Pharmaceuticals. 
   • Government advice and other policy development: None 
   • Paid research activities, fellowships or grants: None 
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Columbia University. By “funding” I mean I will be paid my regular annual salary for the time spent on this committee work. I will personally cover all other expenses relating to my work on behalf of the committee.[ii])
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:  Maureen George

Date:  March 17, 2019

I, Kathleen Hoffman, nominated by and residing in United States of America, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed by Sterigenics, a Sotera Health Company, as SVP of Global EH&S and Technical Services. My responsibilities include leading the company’s global environmental, health, safety and security management program and the technical services and consulting group that supports our facilities and customers.  Other responsibilities include oversight of various regulatory actions and participation with various government and trade association groups on regulatory and technical topics.  We utilize ethylene oxide and radiation for the sterilization and bio reduction of medical products, cosmetics and food products.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: See response to #2.
   • Government advice and other policy development: See response to #2.
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is by a voluntary basis.  However, such funding is very limited because my participation is mainly done on a remote basis.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:             Kathleen Hoffman
Date:               April 7, 2019

I, Jianxin Hu nominated by China, and residing in China, a Member of the Medical and Chemicals Technical Options Committee declare as follows..

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. 2) I am a Professor of Environmental Sciences at Peking University in China. My responsibilities include teaching and researching on environmental management on Chemicals, especially relate to HFCs, ozone-depleting substances, and persistent organically pollutants, as an independent consultant providing strategic, policy and technical advice to government, industry and other non-governmental organizations.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or task forces Unexpected Emissions of CFC-11.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: See following.
   • Government advice and other policy development: See following.
   • Paid research activities, fellowships or grants: My research work has an
   • Other interests:
   • interest in the topics of the Montreal Protocol, because I work for organisations that support the Montreal Protocol in phasing out ODS. Such as in 2015, I had a project which is drafting Chinese HCFCs Phaseout Plan for the government. This project paid by MLF.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is UNEP.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jianxin Hu

Date: March 14, 2019

I, Ryan Hulse, nominated by USE, residing in USA, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. My interests[i], and those of my personal partner and dependents, include the following
2. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
3. I am Fellow at Honeywell International. My responsibilities include leading the discovery team for the Fluorine products division on Honeywell. In this role I am responsible to lead the discovery team that deals with all Fluorinated new products and focuses specifically on Aerosol, Solvent, Refrigerants and Foam Blowing Agents.
4. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   • Proprietary interests: I have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). As part of my work at Honeywell I have developed aerosol and solvent alternatives to CFC and HCFCs. These rights for the patents are wholly owned by Honeywell.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Honeywell has interest in the topics of the Montreal Protocol in that they are developing low global warming potential and non-ozone depletion potential alternatives to current CFC and HCFCs.
   • Government advice and other policy development: none
   • Paid research activities, fellowships or grants: none
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is from Honeywell Int.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Ryan Hulse

Date: March 18, 2019

I, Rabinder N Kaul, residing in India, appointed as member of the Medical and Chemicals Technical Options Committee and TEAP’s Task Force on Unexpected Emissions of CFC-11 under Decision XXX/3 declare as follows:

1. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
2. I presently work for SRF Limited as a consultant. I am also Secretary of REGMA, an industrial association of refrigerant gases manufacturers in India. My responsibilities include work related to the Montreal Protocol and related MEAs and the regulatory issues.
3. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do have some shares in an entity with an interest in the subject
   • Employment, consultancy, directorship or other positions: I am also Secretary of the Refrigerant Gas Manufacturers Association (REGMA)
   • Government advice and other policy development: Do not provide advice on significant issues to a Government in respect of policy.
   • Paid research activities, fellowships or grants: I do not receive paid research activities or any fellowships /grants relevant to the TEAP activity.
   • Other interests: No other interests related to the subject matter of TEAP/Montreal Protocol
5. The source of funding for my participation in the work of the TOC and TEAP’s Task Force on Unexpected emissions of CFC 11. The travel and stay is funded by the Ozone Secretariat as Article 5 participant. Professional services are however voluntary.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TOC and TEAP Temporary Subsidiary Body.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:   Rabinder N Kaul

Date:    17 May,2019

I, DR. JAVAID A. KHAN_, nominated by (add party) AGA KHAN UNIVERSITY, KARACHI, residing in (add party) _PAKISTAN_, a (Member/co-chair) of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies ("the COI Guidelines") as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am (describe your affiliations, including job title, employing organization). My responsibilities include (describe current work interests/areas of focus).
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I (have/ do not have) proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
   • Financial interests: I (have/ do not have) ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (add description of interest; relevant financial relationships between members should be disclosed)
   • Employment, consultancy, directorship or other positions: (describe any interests relevant to the MCTOC activity).
   • Government advice and other policy development: (describe any interests relevant to the MCTOC activity, including any provision of advice to government, organizations or institutions involved in policy development)
   • Paid research activities fellowships or grants: (describe any paid research activities, fellowships or grants relevant to the MCTOC activity)
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is (describe funding arrangements and source²)
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I (have/have not) declined to disclose information falling within paragraph 10 of those Guidelines (if have declined, add the following at the end of this statement "and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose").
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it. 

Name: JAVAID A. KHAN

Date:  May 2019

I, Andy Lindley, nominated by the United Kingdom, residing in the United Kingdom, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. My interests, and those of my personal partner and dependents, include the following Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
2. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
3. I am an independent consultant providing services to Mexichem UK Ltd and EFCTC. My responsibilities include work for the European Fluorocarbon Technical Committee (EFCTC) mainly focused on HFCs and HFOs, their applications and EFCTC website content development and newsletter production.
4. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I receive payment for acting as a consultant to Mexichem UK Ltd and EFCTC. My responsibilities include work for the European Fluorocarbon Technical Committee (EFCTC), mainly focused on HFCs and applications, website content development and newsletter production.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: No Conflict
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is none as no funding is required for my participation as a corresponding member
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Andy Lindley

Date: 17 March 2019

I, Gerald McDonnell, nominated by United Kingdom, residing in United States, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I am Senior Director at DePuySynthes, a Johnson & Johnson company. My responsibilities include contamination control and sterility assurance.
2. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
3. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
4. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
   • Proprietary interests: I do not have) proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I am a minor shareholder in Johnson & Johnson, a user of sterilization technology.
   • Employment, consultancy, directorship or other positions: am an employee for Johnson & Johnson who uses radiation and gas sterilization procedures for product manufacturing.
   • Government advice and other policy development: None.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Johnson & Johnson.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

    

   Name: Dr. Gerald McDonnell

   Date: April 3, 2019

    

    

    

I, Robert J. Meyer, nominated by the United States of America, residing in Virginia (US), a (Member/co-chair) of the Medical and Chemicals Technical Options Committee declare as follows.

1. 1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   2. I am Principal of Drug and Biological Products at Greenleaf Health, Inc., an FDA focused consulting firm. My responsibilities include advising sponsors of therapeutic products on matters related to drug development and regulatory engagement/success.
   3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
   4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
      • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
      • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
      • Employment, consultancy, directorship or other positions: I have engaged in regulatory consulting with companies that have inhalation drug products, though I am salaried and I do not specifically advise on issues related to UNEP actions or issues.
      • Government advice and other policy development: None
      • Paid research activities, fellowships or grants: None
      • Other interests:
   5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is my own finances.
   6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines (if have declined, add the following at the end of this statement “and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose”). 
   7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
   8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
   9. I understand that this DOI will expire no later than one year after I have signed it.

Name:  Robert J. Meyer, MD

Date: 27-March-2019

I, Timothy James Noakes, nominated by the United Kingdom, residing in The United Kingdom, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed by Mexichem (UK) Ltd (a company specialising in fluorinated gases including MDI propellants) as a Technical Associate. My responsibilities include maintaining a global view of the respiratory inhalers market and advancing the technology of MDI propellants and their use.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions. I am a full – time employee of Mexichem (UK) ltd, a leading global manufacturer of HFC gases including HFC 134a. I have worked for Mexichem for 25 years developing and then supporting the sale of medical grades of this propellant for use in MDIs. My main interest is in technical matters relating to use and performance. I am now involved in developing a new lower carbon MDI propellant HFC 152a.
   • Government advice and other policy development: No contacts at present
   • Paid research activities, fellowships or grants: None
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is my employer.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Timothy J. Noakes

Date: 04/04/2019

I, John G. Owens nominated by the Unites States of America, residing in the United States of America, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a lead research specialist at 3M Company, Saint Paul, Minnesota, USA. My responsibilities include product development and environmental impact assessment for fluorinated fluid technologies, including cleaning and deposition solvents and aerosol components.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I to not proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I own shares of stock in my employer, 3M Company, which is an entity with an interest in the Montreal Protocol as a manufacturer of alternatives to ozone depleting substances. Should a conflict arise due to activities related to my employer, I will recuse myself as delineated in Decision XXIV/8.
   • Employment, consultancy, directorship or other positions: Except for my employment at 3M Company, neither I nor my spouse are employed by, do not consult for, do not serve as a director of or hold any other position for any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel.
   • Government advice and other policy development: Neither I nor my spouse provide advice on issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is my employer, 3M company.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: John G. Owens

Date: 13 March 2019

I, Jose Pons, nominated by Venezuela residing in United States, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. 1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   2. I am president of Spray Quimica CA and Sicamu Inc. My responsibilities include managing aerosol filling plants.
   3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
   4. My interests, and those of my personal partner and dependents, include the following
      • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces
      • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
      • Employment, consultancy, directorship or other positions: None
      • Government advice and other policy development: None
      • Paid research activities, fellowships or grants: None
      • Other interests:
   5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Montreal Protocol Secretariat
   6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
   7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
   8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
   9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jose Pons

Date: 3/13/19

I, Hans (J.G.W.) Porre, nominated by Netherlands, residing in Netherlands, member of the Medical and Chemicals Technical Options Committee:

1)   I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.

2)   I am a full-time, salaried employee at Teijin Aramid B.V., based on Delfzijl, which manufactures aramid polymer (poly-paraphenyleenterephtalamide). I work for the company as environmental coordinator. 

3)   This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.

4)   My interests, and those of my spouse and step-son include the following

a.   Proprietary interests: Neither I nor my spouse, have a proprietary interest in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies.
b.   Financial interests: Neither I nor my spouse own or exercise control over shares or bonds in an entity with an interest in the subject matter of the meeting or work except for shareholdings through general mutual funds where we have no control over the selection of shares.  I own no shares of Honeywell.
c.   Employment, consultancy, directorship or other positions: Except for my work with the MCTOC, neither I nor my spouse are employed by, do not consult for, do not serve as a director of or hold any other position for any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel.
d.   Government advice and other policy development: Neither I nor my spouse provide advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.
e.   Paid research activities, fellowships or grants: Neither I nor my spouse are the recipients of any paid research activities or any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

f. Other interests: Neither I nor my spouse have other interests related to the subject matter of the Technology and Economic Assessment Panel or the Montreal Protocol.
 

5)   The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee, comes from Teijin Aramid B.V.

6)   Pursuant to paragraph 11 of the COI Guidelines I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.

7)   I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.

8)   I undertake to make further declarations of interest annually for so long as I remain a member of the Chemicals Technical Options Committee

9)   I understand that this DOI will expire no later than one year after I have signed it.

Signed : Hans (J.G.W.) Porre
Date    : 13th March 2019

I, John Pritchard, nominated by and residing in United Kingdom, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. Until 30 Sept 2018, I was Chief Technology Officer for the Respiratory Drug Delivery business unit of Philips. My responsibilities included research, design, development and market support for nebulisers and valved holding chambers. I am now acting as an independent consultant to clients developing respiratory drugs, devices and digital healthcare, trading under the company name of Inspiring Strategies.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following :
   • Proprietary interests: We do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: My wife and I have minority ownership of shares in various pharmaceutical companies who develop, manufacture and sell respiratory products that are impacted by decisions taken under the Montreal Protocol.
   • Employment, consultancy, directorship or other positions: I consult to a variety of clients, some of whom may be commercially impacted by decisions taken under the Montreal Protocol.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. I receive no funding for my participation in the work of the Medical and Chemicals Technical Options Committee. Travel expenses might in the future be supported either by client relationships or the UK Government.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: JN Pritchard

Date: 3 Apr 2019

I, Rabbur Reza, nominated by Bangladesh (A5), a member of the Medical and Chemical Technical Options Committee, declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I work as full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh and as Managing Director of Nuvista Pharma Ltd., Bangladesh. As the operational leader I am overseeing Company’s business operations, which include pharmaceutical formulation and raw material manufacturing & quality control, research & development, regulatory affairs, training (learning & development management), sales, marketing and brand management, distribution, international business development, informational technology, medical affairs, project management, human resources etc.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following:
   • Proprietary interests: My employer Beximco Pharmaceuticals is the largest MDI manufacturer in Bangladesh and has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs in local and international markets. I have no proprietary interest in alternatives or substitutes to ODS.
   • Financial interests: I do not own stock in companies producing ODS or alternatives or substitutes to ODS, and do not have an interest in the outcome of essential use nominations.
   • Employment, consultancy, directorship or other positions: I work as full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh and as Managing Director of Nuvista Pharma Ltd., Bangladesh. I also serve as a director on the board of BioCare Manufacturing Sdn Bhd., Malaysia. BioCare is involved in manufacturing MDIs. I am also an Executive member of Bangladesh Association of Pharmaceutical Industries and a member of Bangladesh Pharmacy Council. My spouse is a medical practitioner and has no interest in matters before the Protocol.
   • Government advice and other policy development: 
   • Paid research activities, fellowships or grants: 
   • Other interests: 
5. UNEP’s Ozone Secretariat funds my travel expenses for participation on MTOC. 
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Rabbur Reza

Date: 3^rd April 2019

I, Paula Rytilä, nominated by Finland residing in Finland a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. 1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   2. I am Chief Medical Officer, Vice President, Orion Corporation Orion Pharma. My responsibilities include working as CMO responsible for Global Medical Affairs and Pharmacovigilance in R&D organization of the company.
   3.  
   4. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
      • My interests[i], and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
      • Proprietary interests: I (have/ do not have) proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
      • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I own shares of Orion Corporation.
      • Employment, consultancy, directorship or other positions: I am a full-time employee of Orion Corporation Orion Pharma.
      • Government advice and other policy development: none.
      • Paid research activities, fellowships or grants: none.
      • Other interests: none.
   5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is from my employee Orion Corporation Orion Pharma.
   6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
   7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
   8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
   9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Paula Rytilä

Date: 11^th April 2019

I, Raj Sharma nominated by the MTOC Chair residing in UK a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. 1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   2. I am Director of Inhaled Drug Delivery at GSK. My responsibilities include evidence generation and medical affairs activities in Respiratory inhaled medicine
   3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
   4. My interests[i], and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
      • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
      • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I am employed by GSK who manufacture and supply metered dose inhalers
      • Employment, consultancy, directorship or other positions: see above
      • Government advice and other policy development: N/A
      • Paid research activities, fellowships or grants: N/A
      • Other interests: N/A
   5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is GSK
   6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines
   7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
   8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
   9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Raj Sharma

Date: 16 April 2019

I, Peter Sleigh, residing in United Kingdom, appointed as member of the Medical and Chemicals Technical Options Committee and TEAP’s Task Force on Unexpected Emissions of CFC-11 under Decision XXX/3 declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed as a Regulatory Manager for Mexichem UK Limited, a producer and distributor of fluorinated products. My responsibilities include ensuring regulatory compliance particularly in the Europe. Mexichem UK Limited has an interest in the topics of the Montreal Protocol because they sell fluorochemicals controlled by the protocol.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: Neither I nor my spouse, have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: Neither I nor my spouse, have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Except for my work for Mexichem UK Limited, neither I nor my spouse are employed by, do not consult for, do not serve as a director of, or hold any other position for any entity which has an interest in the subject matter of the TEAP and its Task Force.
   • Government advice and other policy development: Apart from providing occasional responses to government initiated public consultations neither I nor my spouse provide advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.
   • Paid research activities, fellowships or grants:- Except for my salary as an employee of Mexichem UK Limited, neither I nor my spouse are the recipients of any paid research activities or any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.
   • Other interests: Neither I nor my spouse have other interests related to the subject matter of the Technology and Economic Assessment Panel or the Montreal Protocol.
5. The source of funding for my participation in the work of the TEAP Task Force on Unexplained Emissions of CFC-11 is as part of my day to day Regulatory Manager role for Mexichem UK Limited.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP Temporary Subsidiary Body.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Peter Sleigh

Date: May 2019

I, Jørgen Vestbo, nominated by Ministry of Environment and Food of Denmark, residing in Denmark, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. 1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   2. I am Professor of Respiratory Medicine at the University of Manchester, Manchester, UK. My responsibilities include research and teaching in respiratory medicine and management of patients; my area of focus is on chronic obstructive pulmonary disease (COPD) and inhaled therapies.
   3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
   4. My interests, and those of my personal partner and dependents, include the following:
      • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
      • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
      • Employment, consultancy, directorship or other positions: 
        I have received honoraria from pharmaceutical companies (AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK and Novartis) for advising and presenting. All work is being invoiced through a Danish tax registered one-man company, Vestbo medical, VAT Reg No 21215430.
        My son, Jakob Vestbo, is a Key account manager of Chiesi in Denmark. 
        My wife, Inge Vestbo, worked from 1985 to 2009 in the pharmaceutical industry in Denmark and the UK.
      • Government advice and other policy development: 
        I am Chair of the Advocacy Council of the European Respiratory Society. 
        I am a member of the Scientific Committee of the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) responsible for a widely cited strategy document on diagnosis and management of COPD. 
        I am an advisor to WHO (Geneva) on non-communicable diseases. 
      • Paid research activities, fellowships or grants: I have previously held grants from GSK and together with a junior researcher in my group (Alexander Mathioudakis) I hold a grant from Boehringer-Ingelheim UK (£70,000). 
      • Other interests: None.
   5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is personal (or from own NHS hospital endowment account).
   6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
   7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
   8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
   9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jørgen Vestbo

Date: 14 March 2019

I, Kristine Whorlow AM, nominated by the Australian Government, residing in Melbourne, Australia, a Member) of the Medical and Chemicals Technical Options Committee declare as follows.

1. 1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   2. I am the recently retired CEO of the National Asthma Council Australia. My responsibilities included producing the national treatment guidelines for asthma and implementing these through an extensive national program of primary care health professional education as well as conducting national promotional campaigns to promote community asthma education. I was also responsible for conducting outreach asthma education activities in Asia Pacific.
   3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
   4. My interests, and those of my personal partner and dependents, include the following
      • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
      • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
      • Employment, consultancy, directorship or other positions: none relevant.
      • Government advice and other policy development: none relevant.
      • Paid research activities, fellowships or grants: none.
      • Other interests: none
   5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is myself.
   6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I (have/have not) declined to disclose information falling within paragraph 10 of those Guidelines.
   7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
   8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
   9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Kristine Whorlow

Date: March 25, 2019

I, Professor Ashley Woodcock, residing in Manchester UK, nominated to TEAP by the United Kingdom, declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Consultant Respiratory Physician and Professor of Respiratory Medicine.
3. 3) This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. 4) My interests, and those of my personal partner and dependents include the following (if answer is yes describe briefly)
   • Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: I carry out research in novel respiratory treatments, which do not use CFCs or HFCs. I act as non-Executive Chairman for three biotechnology companies (Clinical Trials, Allergy Diagnostics, Cough Therapy) none of which have any relevance to the Montreal Protocol.
   • Government advice and other policy development: I am an invited member of the low carbon inhaler working group for the UK NHS Sustainable Development Unit
   • Paid research activities, fellowships or grants: NO
   • Other interests:
5. The source of funding for my participation in the work of TEAP : Travel/Hotels are supported by Manchester University NHS Foundation Trust; My time commitment is voluntary
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.
9. I understand that this DOI will expire no later than one year after I have signed it.

Signed: Ashley Woodcock

Date: 19 Feb 2018

I, Nee Sun CHOONG KWET YIVE, nominated by Government of Mauritius, residing in Mauritius, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. 1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   2. I am Associate Professor in Chemistry at the University of Mauritius. My responsibilities include teaching Physical and Analytical at undergraduate and post graduate levels and doing research in the field of environmental chemistry.
   3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
   4. My interests[1], and those of my personal partner and dependents, include the following
      • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
      • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
      • Employment, consultancy, directorship or other positions: None
      • Government advice and other policy development: I participated in national meetings organized by the Ministry of Environment, Mauritius to phase out ODSs.
      • Paid research activities, fellowships or grants: None
      • Other interests: None
   5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Ozone Secretariat.
   6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
   7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
   8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
   9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Nee Sun Choong Kwet Yive

Date: 13 March 2019 

I, You Yizhong, nominated by China, residing in China, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am :1.Chief Editor of Journal of Aerosol Communication. 2.President of Aerosol Committee of China Packaging Federation. 3.Chief Pharmacist,Associate Chief Physician of The First People’s Hospital of Changzhou,China. My responsibilities include investigate aerosol and inhale drugs.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests[i], and those of my personal partner and dependents, include the following .
   • Proprietary interests: I do not have  proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have  ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions. No any intrest relevant to the MCTOC activity.
   • Government advice and other policy development: I have no any interests relevant to the MCTOC activity, including any provision of advice to government, organisations or institutions involved in policy development.
   • Paid research activities, fellowships or grants:no any ities, fellowships or grants relevant to the MCTOC activity
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is UNEP
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:

Date: Mach 15,2019

I, _ZHANG Jianjun, residing in and nominated by China to TEAP，a Member of TEAP and co-chair of MCTOC declare as follows.

1) I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.

2) I am the general manager of Zhejiang Chemical Industry Research Institute Co. Ltd(ZCIRI), a Zhejiang based State-owned company that engages on the research and development of fluorochemicals and pesticide. My main activity for ZCIRI is the management of R&D on fluorochemicals which mainly includes the development of ODS alternatives.

3) This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.

4) My interests, and those of my personal partner and dependents include the following (if answer is yes describe briefly)

• Proprietary interests: I do not have proprietary interest in substance, technology or process to be considered by TEAP or any TOC or any temporary subsidiary body.
• Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
• Employment, consultancy, directorship or other positions: I am fully employed by Zhejiang Chemical Industry Research Institute (ZCIRI). ZCIRI has an interest in the topics of the Montreal Protocol because it is also a National ODS Alternatives Engineering Research Center of China and engages on the research and development of ODS alternatives and their applied technologies, development of technologies for ODS destruction and conversion. In addition, its mother company-Sinochem Lantian Co. Ltd. is one of the major manufacturer of ODS alternatives in China.
• Government advice and other policy development: None
• Paid research activities, fellowships or grants: None
• Other interests: None

5) The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee and TEAP is supported by UNEP

6)   Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 

7)   I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.

8)   I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.

9)   I understand that this DOI will expire no later than one year after I have signed it.

Signed: Zhang Jianjun

Date: 12^th  February, 2019

I, Lifei Zhang, nominated by China, residing in China, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Professor of National Research Center for Environmental Analysis and Measurement in China. My responsibilities include: Laboratory use and standard analytical method on carbon tetrachloride; Persistent organic pollutants unintentionally produced during tetrachloroethylene production; Chemical decomposition technologies on organic compounds and it’s mechanisms.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: None.
   • Government advice and other policy development:
   • Paid research activities, fellowships or grants:
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Lifei Zhang

Date: March 18, 2019